deaths from glp-1 Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease GLP-1 medications get at the

These symptoms typically occur during treatment initiation or dose escalation and often diminish over time as the body adjusts to the medication

[DOI] [PubMed] [Google Scholar] [144].Dominguez Rieg JA, Rieg T, Diabetes Obes Metab 2019, 21 Suppl 2, 43

An analysis of nine observational studies showed a significant reduction in CV and renal outcomes with the GLP-1RA/SGLT2i combination, compared with GLP-1RA and SGLT2i monotherapy [135]

They found that people taking GLP-1 medications had a 40 percent lower risk of pulmonary embolism (PE), the potentially fatal condition that occurs when a blood clot travels to the lungs